170814 ⎘
Detection or diagnosis of diseases; Musculoskeletal or connective tissue disorders Crystal induced conditions; Gout
METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
#2METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
#3METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
#4Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
#5Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
#6Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
#7ANTI-CARBAMYLATED PROTEIN ANTIBODIES AND THE RISK FOR ARTHRITIS
#8Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
#9METHOD FOR DETERMINING THE ANTIOXIDANT CAPACITY OF A BIOLOGICAL SAMPLE AND RELATED KIT
#10METHOD AND KIT FOR DETERMINING THE PRESENCE OF MONOSODIUM URATE CRYSTALS IN JOINT SYNOVIAL FLUID
#11ANTI-CARBAMYLATED PROTEIN ANTIBODIES AND THE RISK FOR ARTHRITIS
#12Inhibiting the onset of gout
#13Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
#14Anti-carbamylated protein antibodies and the risk for arthritis
#15Methods and devices for diagnosis of particles in biological fluids
#16Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
#17Method for determining the propensity for calcification
#18METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
#19Methods and devices for diagnosis of particles in biological fluids
#20PERSONALISED MEDICINE
#21Method for determining the propensity for calcification
#22Anti-carbamylated protein antibodies and the risk for arthritis
#23Method and apparatus for detecting the presence of intraerythrocytic parasites
#24Methods for Assessing Tophus Response During Urate Lowering Therapy in Treatment Tophaceous Gout
#25Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
#26ALPK1 GENE VARIANTS IN DIAGNOSIS RISK OF GOUT
#27Assays for disease-associated crystals in biological samples